ADGRD1 promotes bladder cancer progression and angiogenesis via the PI3K/AKT/mTOR-mediated pro-angiogenic secretome - Report - MDSpire

ADGRD1 promotes bladder cancer progression and angiogenesis via the PI3K/AKT/mTOR-mediated pro-angiogenic secretome

  • By

  • Chen Li

  • Zhichao Yang

  • Jialei Zhang

  • Xiaodong Yan

  • Hongwei Su

  • May 28, 2026

  • 0 min

Share

Clinical Report: ADGRD1 Enhances Bladder Cancer Advancement and Angiogenesis

Overview

ADGRD1 is associated with advanced-stage bladder cancer and may promote tumor growth and angiogenesis through the activation of the PI3K/AKT/mTOR signaling pathway.

Background

Bladder cancer is a leading cause of cancer-related mortality, particularly in advanced stages. Understanding the molecular mechanisms driving tumor progression is crucial.

Data Highlights

FindingDetails
ADGRD1 ExpressionEnriched in advanced-stage and high-grade BLCA
Prognostic ValueAssociated with overall survival and progression-free interval
Functional AssaysPromotes BLCA cell proliferation, migration, invasion, and angiogenesis
Xenograft ModelsEnhanced tumor growth and angiogenesis in vivo
Secretome AnalysisUpregulates VEGF, PDGF, and IL-8
Pathway ActivationIncreased phosphorylation of PI3K/AKT/mTOR components

Key Findings

  • ADGRD1 is significantly upregulated in advanced bladder cancer.
  • High ADGRD1 expression correlates with poor prognosis.
  • ADGRD1 enhances cell proliferation, migration, and invasion in vitro.
  • ADGRD1 promotes angiogenesis through a pro-angiogenic secretome.
  • Activation of the PI3K/AKT/mTOR pathway is mediated by ADGRD1.

Clinical Implications

Further research is needed to explore the potential of ADGRD1 in bladder cancer management.

Conclusion

ADGRD1 is identified as a driver of bladder cancer progression and angiogenesis.

Related Resources & Content

  1. Author(s)/Org, Source, Year -- Title
  2. The ASCO Post — EGFR a Potential Target in Muscle-Invasive Bladder Cancer With Basal-Like Phenotype
  3. Frontiers in Oncology — GLIS3 drives epithelial–mesenchymal transition and cancer stem–like traits in stomach adenocarcinoma via TGFBR3–Hedgehog signaling
  4. Journal of Gastroenterology — Agonistic GITR treatment enhances antitumor immune responses and suppresses tumor progression in pancreatic ductal adenocarcinoma
  5. The ASCO Post — KRYSTAL-1 Update: Adagrasib Yields Benefit in Variety of KRAS G12C–Mutated Tumors Related Articles
  6. EAU Guidelines on Muscle-invasive and Metastatic Bladder Cancer
  7. FDA approves durvalumab for muscle invasive bladder cancer
  8. FDA approves pembrolizumab with enfortumab vedotin for muscle invasive bladder cancer
  9. ESMO Clinical Practice Guideline interim update on first-line therapy in advanced urothelial carcinoma - ScienceDirect
  10. Enfortumab vedotin plus pembrolizumab in untreated locally advanced or metastatic urothelial carcinoma: 2.5-year median follow-up of the phase III EV-302/KEYNOTE-A39 trial - ScienceDirect
  11. Avelumab First-line Maintenance for Advanced Urothelial Carcinoma: Long-term Outcomes from the JAVELIN Bladder 100 Trial in Patients with Nonvisceral or Lymph Node-only Disease - PubMed
  12. Adjuvant nivolumab (NIVO) vs placebo (PBO) for high-risk muscle-invasive urothelial carcinoma (MIUC): Additional efficacy outcomes including overall survival (OS) in patients (pts) with muscle-invasive bladder cancer (MIBC) from CheckMate 274. | Journal of Clinical Oncology
  13. Frontiers | Molecular mechanisms and translational advances in bladder cancer: from driver genes to precision therapy
  14. Ramucirumab plus docetaxel versus placebo plus docetaxel in patients with locally advanced or metastatic urothelial carcinoma after platinum-based therapy (RANGE): overall survival and updated results of a randomised, double-blind, phase 3 trial - PMC
  15. FDA approves erdafitinib for locally advanced or metastatic urothelial carcinoma | FDA
  16. FDA approves mitomycin intravesical solution for recurrent low-grade intermediate-risk non-muscle invasive bladder cancer | FDA
  17. EAU Guidelines on Non-muscle-invasive Bladder Cancer - Uroweb

Original Source(s)

ADGRD1 promotes bladder cancer progression and angiogenesis via the PI3K/AKT/mTOR-mediated pro-angiogenic secretome

  • by Chen Li, Zhichao Yang, Jialei Zhang, Xiaodong Yan, Hongwei Su

  • May 28, 2026

Related Content

Gastric-type endocervical adenocarcinoma with Peutz-Jeghers syndrome: a case report and literature review

Validation of a cervical CDO1/CELF4 methylation test for endometrial cancer: a prospective paired-sample comparison with intrauterine specimen

Predicting preoperative axillary lymph node metastasis to guide surgical decisions in invasive breast cancer